| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Regulatory Decision example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
Regulatory Decision example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
Regulatory Decision example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Neuronetics, Inc.$1.76
+0.12 (+7.21%)
D 28Pipeline Score MedTech · Commercial
Market Cap
83.51 M
EPS
-0.55
P/E Ratio
-
Value Trade
2.54 M
SEC Financials
Q1 2026Dilution Risk
Revenue
34.45 M
R&D Expenses
1.36 M
Operating CF
-9.42 M
Total Assets
125.44 M
Total Liabilities
108.38 M
Equity
13.27 M
D/E Ratio
12,345
-4.76 %
Week
-20.53 %
1 Month
-9.77 %
3 Month
-6.98 %
6 Month
-91.97 %
5 Year
-95.2 %
All Time
Cash Data
Cash Position
18.96 M
Monthly Burn
3.14 M
Runway
4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
2.07 M
52 Week Range
0.80 - 4.85
% held by Insiders
64.47 %
% held by Institutions
33.55 %
Enterprise Value
153.47 M
Total Shares
69.50 M
Short %
39.67 %
Float Shares
26.62 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D28
Pipeline Score $66M
Pipeline ValueValuation Signal
1
Drugs Scored0.8x
rNPV / MCap Top 30%
Micro Cap (rank 639 of 911)
Percentile RankNeuronetics, Inc. faces pipeline headwinds (28/100), with $1.4B risk-adjusted pipeline value, led by Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Repetitive Transcranial Magnetic Stimulation Unknown | Major Depressive Disorder | Phase 3 | NCT00104611 | 51% | $1.4B | COMPLETED | 286 | - | - | Nov 1, 2005 | - | Sep 20, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NeuroStar | major depressive disorder (MDD) | — | 2023-02-21 | over 7,000 patients, 36 sessions | Neuronetics Sponsors the 5th International Brain Stimulation Conference Read More | |
NeuroStar | major depressive disorder (MDD) | — | 2023-02-21 | over 7,000 patients, 36 sessions | Neuronetics Sponsors the 5th International Brain Stimulation Conference Read More | |
NeuroStar | major depressive disorder (MDD) | — | 2023-02-21 | over 7,000 patients, 36 sessions | Neuronetics Sponsors the 5th International Brain Stimulation Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STIM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
STIM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STIM▲ +10.6%on this news
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
Neuronetics, Inc. will participate in the B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026. The event will feature a panel discussion on commercializing novel neuropsychiatric drugs, alongside Compass Pathways. Management will also hold one-on-one meetings with institutional investors, although there will be no live webcast of the discussion.
Read more →STIM▼ -6.6%on this news· ran to -23% by day 3
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
Neuronetics, Inc. is participating as a Silver Sponsor at the 2026 Clinical TMS Society Annual Meeting, where it will present real-world data from its TrakStar database. The presentations will focus on the effectiveness of transcranial magnetic stimulation (TMS) for mental health conditions, including major depressive disorder. This participation underscores Neuronetics' commitment to advancing TMS research and evidence-based treatment options.
Read more →STIM▼ -6.6%on this news· ran to -23% by day 3shared move
Neuronetics Appoints Robert Greene as Senior Vice President Sales
Neuronetics, Inc. has appointed Robert Greene as Senior Vice President Sales, effective June 1, 2026. Greene brings significant experience in leading sales organizations within the healthcare sector. His appointment is expected to enhance Neuronetics' commercial strategy and sales efforts, particularly in neurohealth products.
Read more →STIM▼ -13.9%on this news
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
Neuronetics, Inc. announced a strategic partnership with ANT Neuro to integrate advanced neuronavigation technology into its NeuroStar Advanced Therapy System. This collaboration will enhance treatment delivery by incorporating real-time spatial tracking and 3D visualization, aimed at improving patient outcomes in neurohealth disorders. The partnership will be showcased at upcoming industry meetings, with a broader rollout planned for the latter half of 2026. The integration seeks to meet the evolving needs of healthcare providers in the TMS market.
Read more →STIM▲ +7.4%on this news· ran to -18% by day 3
Neuronetics Reports First Quarter 2026 Financial and Operating Results
Neuronetics, Inc. reported its first quarter 2026 financial results, showing an 8% revenue increase to $34.5 million compared to the previous year. The company also noted a significant reduction in cash used for operations and an expansion of its TMS clinical policy, which broadens treatment access. However, the net loss for the quarter was $10.8 million, and gross margins decreased slightly.
Read more →STIMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. announced the granting of inducement awards to six non-executive employees as part of their employment inducement strategy, in compliance with NASDAQ Listing Rule 5635(c)(4). The awards were approved by the Compensation Committee and are structured with vesting dependent on continued employment. This initiative reflects Neuronetics' commitment to expanding its workforce while enhancing innovations in treatment for mental health disorders. Additionally, the company continues to support its NeuroStar Advanced Therapy System, focusing on delivering effective non-invasive treatments for major depressive disorder and other neurohealth conditions.
Read more →STIM▼ -5.1%on this news
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. will release its first quarter 2026 financial results on May 5, 2026, before market open. A conference call to discuss these results will follow at 8:30 a.m. ET. The company focuses on improving the quality of life for patients with neurohealth disorders through its NeuroStar Advanced Therapy.
Read more →STIMOptum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
Neuronetics, Inc. announced that Optum/United Healthcare/United Behavioral Health has expanded its TMS policy to allow psychiatric mental health nurse practitioners to order and administer NeuroStar therapy. This change enhances access to treatment for millions of patients across 26 states and Washington, D.C. The update recognizes the vital role of nurse practitioners in mental healthcare, particularly for those who have not responded to traditional medications.
Read more →STIM▼ -10.2%on this news· ran to -23% by day 3
Neuronetics Announces Chief Financial Officer Transition
Neuronetics, Inc. has announced the departure of CFO Steven E. Pfanstiel, who will leave to pursue another opportunity. He will assist in the transition until May 1, 2026. The company has reaffirmed its financial guidance for the fiscal year 2026, emphasizing its commitment to improving mental health treatment options.
Read more →STIM▼ -10.2%on this news· ran to -23% by day 3shared move
Neuronetics Comments on Letter from Pointillist Family Office
Neuronetics, Inc. responded to a letter from Jorey Chernett of Pointillist Family Office, emphasizing its commitment to maximizing shareholder value. The Board appreciates shareholder engagement and agrees that the company's current valuation does not fully reflect its business strength. Neuronetics aims to enhance long-term value through strategic priorities.
Read more →STIM▲ +15.8%on this newsshared move
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business
Jorey Chernett, the largest independent shareholder of Neuronetics, has urged the Board to conduct a comprehensive review of strategic alternatives, including the potential sale of the TMS business. Chernett believes that separating the TMS and clinic businesses could unlock significant shareholder value, estimating a 5-7x increase in equity value. He emphasizes that the anticipated synergies from the merger have not been realized, and that a focused approach could enhance the clinic business's performance.
Read more →STIM▼ -9.9%on this news
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Neuronetics reported a strong financial performance for Q4 and full year 2025, with total revenue increasing significantly, driven by the acquisition of Greenbrook TMS. The company appointed Dan Reuvers as CEO, aiming to leverage his experience for future growth. Despite a net loss, operational cash flow improved, and the company anticipates continued revenue growth in 2026.
Read more →STIM▼ -9.9%on this newsshared move
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Neuronetics, Inc. has appointed Dan Reuvers as the new President and CEO, effective March 23, 2026. Reuvers, who has over three decades of experience in medical technology, succeeds Keith Sullivan, who is retiring after five and a half years. The Board expressed confidence in Reuvers' ability to drive growth and expand treatment access for patients suffering from neurohealth disorders.
Read more →STIMNeuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. plans to release its fourth quarter 2025 financial results on March 17, 2026, prior to market opening. A conference call will follow at 8:30 a.m. ET to discuss these results. The company focuses on innovative neurohealth therapies, including the NeuroStar Advanced Therapy, aimed at improving mental health outcomes.
Read more →STIM▲ +23.3%on this news
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Neuronetics, Inc. reported strong preliminary unaudited financial results for Q4 and full year 2025, with revenues reaching $41.8 million and $149.2 million respectively. The company experienced significant growth in both NeuroStar and clinic revenues, alongside positive operating cash flow. The results reflect successful commercial execution and increased demand for their neurohealth therapies.
Read more →STIM▼ -12.8%on this news
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Neuronetics, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The management team will engage in a fireside chat at 12:30 p.m. ET, which will be accessible to registered attendees. Neuronetics is recognized for its innovative neurohealth therapies, particularly the NeuroStar Advanced Therapy System.
Read more →STIMTRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
Neuronetics, Inc. announced that TRICARE West has expanded its coverage for NeuroStar TMS therapy to include adolescents aged 15 and older struggling with depression. This policy change, effective immediately, aims to improve access to mental health treatment for military families. NeuroStar TMS is recognized as a safe and effective option for adolescents, particularly given the limited medication options available.
Read more →STIMNeuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
Neuronetics reported a strong financial performance for Q3 2025, achieving $37.3 million in total revenue, marking an 11% growth year-over-year. The company also announced CEO Keith J. Sullivan's retirement effective June 30, 2026, and plans to search for his successor. Additionally, New York State Medicaid has expanded coverage for TMS therapy, enhancing access for patients with major depressive disorder.
Read more →STIM▼ -6.9%on this newsshared move
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
Neuronetics has entered a three-year exclusive partnership with Elite DNA Behavioral Health to provide transcranial magnetic stimulation (TMS) devices at over 30 locations. This collaboration aims to enhance patient access to TMS therapy and improve operational support services. The partnership reflects a commitment to advancing mental health treatment and ensuring comprehensive care for patients.
Read more →STIM▲ +5.5%on this news
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. plans to release its third quarter 2025 financial results on November 4, 2025, before the market opens. A conference call will follow at 8:30 a.m. ET to discuss these results. The company is recognized for its NeuroStar Advanced Therapy, a leading non-invasive treatment for major depressive disorder (MDD). Neuronetics continues to enhance its offerings in the neurohealth sector.
Read more →STIMNew York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
Neuronetics, Inc. announced that New York State Medicaid will cover Transcranial Magnetic Stimulation (TMS) therapy for adults with major depressive disorder starting October 1, 2025. This policy will benefit nearly 5.4 million individuals, enhancing access to an evidence-based treatment known for its high response and remission rates. Neuronetics aims to work with providers to further expand access across the nation.
Read more →STIMNeuronetics Reports Second Quarter 2025 Financial and Operating Results
Neuronetics, Inc. reported strong financial results for Q2 2025, with total revenue reaching $38.1 million, a notable increase from the previous year. The company achieved record revenue at its Greenbrook clinics, contributing significantly to an overall 132% increase in revenue compared to Q2 2024. However, they also reported a net loss of $(9.8) million, and a decrease in gross margin due to the integration of Greenbrook's business. Additionally, Neuronetics received $10 million in funding to support further growth and expansion.
Read more →STIMNeuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
Neuronetics, Inc. will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. CEO Keith Sullivan is scheduled to speak at 1:30 PM ET. The presentation will be accessible to registered attendees for 14 days post-event. Neuronetics is known for its NeuroStar Advanced Therapy, a leading treatment for major depressive disorder.
Read more →STIMNeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
Neuronetics, Inc. announced a publication in JAACAP Open showcasing the efficacy of NeuroStar TMS in treating major depressive disorder among adolescents and young adults. The study revealed that approximately 70% of participants experienced clinically meaningful improvement. Following FDA clearance as an add-on therapy for adolescents, there has been a notable increase in treatment uptake. The findings affirm NeuroStar's role in providing effective mental health solutions.
Read more →STIM▲ +8.8%on this news
Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. is set to report its second quarter 2025 financial and operational results on August 5, 2025, prior to market open. A conference call to discuss these results will begin at 8:30 a.m. Eastern Time on the same day. The company emphasizes its dedication to improving mental health through its NeuroStar Advanced Therapy, which has successfully treated millions of patients with conditions like MDD and OCD.
Read more →STIMNeuronetics Appoints New Chief Financial Officer Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer followi
Neuronetics has announced the appointment of Steven Pfanstiel as the new Chief Financial Officer, effective July 15, 2025, succeeding Steve Furlong. Mr. Furlong will transition to a Senior Advisor role until March 2026 to ensure continuity during this change. Neuronetics is reaffirming its financial guidance for the upcoming quarters while highlighting its strategic focus on expanding access to mental health treatments, aided by Pfanstiel's expertise. The company remains optimistic about achieving positive cash flow in the third quarter of 2025.
Read more →STIMNeuronetics Appoints New Chief Financial Officer
Neuronetics, Inc. has appointed Steven Pfanstiel as the new Chief Financial Officer, effective July 15, 2025, replacing Steve Furlong, who will transition to Senior Advisor. The company is reaffirming its financial guidance for 2025, emphasizing successful integration of Greenbrook operations. Pfanstiel brings over two decades of experience in healthcare finance and previously served as CFO at Marinus Pharmaceuticals. Neuronetics aims to continue expanding access to mental health treatments and achieve positive cash flow in the third quarter of 2025.
Read more →STIMNeuronetics Reports Second Quarter 2025 Financial and Operating Results Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue
Neuronetics, Inc. reported its second quarter 2025 financial results, highlighting a total revenue of $38.1 million, an impressive growth of 132% from the previous year. The company's success is attributed to the acquisition of Greenbrook TMS Inc., which generated a record clinic revenue of $23 million. Despite the positive revenue growth, Neuronetics faced a net loss of $9.8 million and a significant drop in gross margin. The company also received an additional $10 million in funding, demonstrating continued investor confidence.
Read more →STIMNeuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
Neuronetics, Inc. announces its participation as a Silver Sponsor at the 2025 Clinical TMS Society Annual Meeting in San Diego. The company will present key data from the TrakStar database, highlighting clinical outcomes of TMS therapy using NeuroStar devices compared to Brainsway devices. Additionally, Greenbrook Mental Wellness Centers has launched a program to evaluate personalized TMS protocols, which has shown operational feasibility. The presentations aim to enhance understanding of TMS effectiveness in treating Major Depressive Disorder, particularly among elderly patients.
Read more →STIMNeuronetics Set to Join Russell 2000 and Russell 3000 Indexes
Neuronetics, Inc. is set to join the Russell 3000 and Russell 2000 Indexes after the annual reconstitution ends on June 30, 2025. This inclusion serves as a significant endorsement of the company's operations and growth strategy, expanding its visibility to institutional investors. The company continues to provide innovative neurohealth treatments and is on track for positive cash flow in 2025. CEO Keith J. Sullivan emphasized that this milestone reflects their commitment to transforming mental healthcare.
Read more →STIMNeuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
Neuronetics, Inc. has announced the inaugural National TMS Therapy Awareness Day, aimed at promoting transcranial magnetic stimulation (TMS) for treating major depressive disorder during Mental Health Awareness Month. This annual event will take place on May 14 and seeks to emphasize TMS as a viable, non-drug option for patients who have not found relief through traditional antidepressants. The company plans to share patient experiences and encourage broader conversations about mental health. NeuroStar TMS, already recognized for its safety and effectiveness, continues to expand its reach, recently receiving FDA clearance for adolescent use.
Read more →STIMNeuronetics Reports First Quarter 2025 Financial and Operating Results MALVERN, PA., May 6 2025 Neuronetics, Inc., (NASDAQ: STIM) (the Company or Neuronetics ) a vertically integrated, commercial stage, medical technolog
Neuronetics, Inc. reported robust financial results for the first quarter of 2025, with total revenues reaching $32.0 million, an 84% increase from the previous year, driven in part by the recent acquisition of Greenbrook. The company emphasized its focus on innovative mental health solutions, expanding insurance coverage for adolescent treatments, and strengthening its financial position through a successful stock offering. However, Neuronetics also faced challenges, including an increased net loss and a decrease in gross margin. Looking ahead, the company anticipates positive cash flow by the third quarter of 2025.
Read more →STIMNeuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. is set to release its first quarter 2025 financial and operating results on May 6, 2025, prior to the market open. A conference call will follow at 8:30 a.m. Eastern Time to discuss the outcomes. The company is recognized as a leader in neuroscience, particularly for its NeuroStar Advanced Therapy, which offers a non-invasive treatment option for patients with neurohealth disorders.
Read more →STIMNeuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. has updated its financial results for the fourth quarter and full year of 2024, reflecting an increase in revenue. Notably, the company continues to face significant net losses, with a reported loss of $43.7 million for the full year, complicating its path to profitability. The updated financial statements incorporate revisions related to the acquisition of Greenbrook TMS Inc. As Neuronetics expands its treatment offerings for mental health, market responses may hinge on its ability to manage costs and demonstrate clear financial gains moving forward.
Read more →STIM▲ +18.8%on this news
Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. reported its financial results for Q4 and full year 2024, revealing an 11% revenue increase to $22.5 million in Q4, largely driven by the acquisition of Greenbrook TMS. The company aims for a dual objective of achieving double-digit revenue growth and becoming cash flow positive by Q3 2025. Despite the positive revenue trends, Neuronetics reported a net loss of $(12.2) million for Q4, a significant rise compared to the previous year. The operational transformation and enhanced market presence indicate a potential for sustainable growth in the neurohealth sector.
Read more →STIM▼ -14%on this news
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. has announced its plans to release its fourth quarter 2024 financial and operating results on March 4, 2025, prior to market opening. The company will also host a live conference call at 8:30 a.m. Eastern Time on the same day to discuss these results. Neuronetics is dedicated to providing non-invasive therapies for mental health disorders, with its NeuroStar Advanced Therapy recognized as a leading treatment for major depressive disorder and anxiety symptoms. The upcoming results and conference call are expected to provide insights into the company's performance and future direction.
Read more →STIM▼ -13.8%on this news
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock
Neuronetics, Inc. announced the pricing of an underwritten public offering amounting to $18 million, comprising 8 million shares at a price of $2.25 each. The company plans to utilize the proceeds for general corporate purposes, including sales and marketing, research and development, and working capital needs. The offering is expected to close on February 10, 2025, subject to customary closing conditions. Canaccord Genuity LLC is the sole bookrunner for this offering.
Read more →STIM▲ +8.9%on this news· ran to +20% by day 3shared move
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock MALVERN, PA.
Neuronetics, Inc. has announced the launch of an underwritten public offering of its common stock. The offering is subject to market conditions and includes a potential grant of a 30-day option for underwriters to purchase additional shares. Canaccord Genuity LLC is acting as the sole bookrunner for the offering. The company has a history of losses which raises concerns among investors regarding its ability to execute its business strategy effectively.
Read more →STIM▲ +36.8%on this news
Neuronetics Provides Business Update and Issues 2025 Guidance Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectively Closed acquisition of Greenbrook TMS effective as of
Neuronetics announced its preliminary financial results for Q4 and FY 2024, reporting revenues of $22.1 million and $74.5 million, respectively. The company also confirmed the completion of its acquisition of Greenbrook TMS, which is expected to enhance its operational capacity and profitability. For FY 2025, Neuronetics anticipates a reduction in cash burn and expects to achieve cash flow breakeven in the third quarter. The integration efforts and strategic initiatives are aimed at expanding patient access to mental health treatments and driving shareholder value.
Read more →STIMNeuronetics and Greenbrook TMS Announce Closing of Transaction MALVERN, Pa. and TORONTO, On.
Neuronetics, Inc. has successfully completed its acquisition of Greenbrook TMS, resulting in the formation of a Combined Company aimed at enhancing mental health therapy. This transaction involves the exchange of Greenbrook shares for Neuronetics shares and will lead to the removal of Greenbrook from public trading markets. Both companies' leadership express confidence that the merger will improve the delivery of mental health treatments and support business growth. The Combined Company will continue operating under the Neuronetics name, leveraging enhanced resources and a unified strategy.
Read more →STIM▲ +6.3%on this news· ran to +28% by day 3
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics, Inc. (NASDAQ: STIM) will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. The presentation is aimed at showcasing their innovative NeuroStar Advanced Therapy, a non-invasive treatment for neurohealth disorders. This therapy has been shown to improve the quality of life for patients who do not respond to traditional medication. A live audio webcast of the presentation will be accessible on the company's investor relations page.
Read more →STIM▼ -37.3%on this news
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. reported record financial results for Q3 2024, achieving total revenues of $18.5 million, a 4% increase from the prior year. The company is positioning itself as a leader in U.S. mental health care through the approved acquisition of Greenbrook TMS. This strategic move aims to enhance patient access and service offerings, while the company also reported strong efficacy results for its NeuroStar TMS therapy in adolescents with major depressive disorder. However, Neuronetics continues to post net losses, which raises concerns about profitability in the near term.
Read more →STIM▼ -37.3%on this news
Correction: Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. reported a record revenue of $18.5 million for Q3 2024, a 4% increase from the previous year. The acquisition of Greenbrook TMS has been approved and is anticipated to strengthen Neuronetics' position in the mental health sector. Despite the positive revenue growth, the company noted an increased net loss of $13.3 million compared to the prior year. The recent findings on NeuroStar's effectiveness in treating adolescent depression further bolster its market position.
Read more →STIMNeuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. plans to release its third quarter 2024 financial results on November 12, 2024, before market opening. A conference call is scheduled for the same day at 8:30 a.m. Eastern Time to discuss these results. The company focuses on mental health innovations, specifically its NeuroStar Advanced Therapy, which has shown effectiveness for patients who have not responded to traditional medications.
Read more →STIM▲ +7.6%on this news
Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings Malvern, PA and Toronto, ON
Neuronetics and Greenbrook TMS have received an interim court order enabling Neuronetics to acquire all outstanding shares of Greenbrook in an all-stock transaction. The boards of both companies have unanimously recommended the arrangement, which is set for a shareholder vote on November 8, 2024. Upon completion, Neuronetics shareholders will own approximately 57% of the new entity, with Greenbrook shareholders holding 43%. The arrangement's approval is contingent on securing supportive votes from shareholders and adhering to regulatory requirements.
Read more →STIMUnderstanding the Benefits of Neuronetics' Greenbrook Acquisition
Neuronetics has announced its acquisition of Greenbrook TMS, which is anticipated to create significant growth opportunities through synergies between the two companies. There are optimistic projections regarding the combined operations and market impact post-acquisition. However, uncertainties and risks accompany this announcement, including regulatory approvals and the combined company's ability to navigate a competitive market landscape. Neuronetics' management remains cautious, highlighting the need for thorough assessments and adjustments as the deal progresses.
Read more →STIM▲ +16.3%on this news· ran to +35% by day 1
Fireside Chat Keith Sullivan President & CEO, Neuronetics, Inc. Bill Leonard President & CEO, Greenbrook TMS Forward Looking Statements This presentation contains estimates and other statistical data prepared by independ
Neuronetics, Inc. and Greenbrook TMS are engaging in a transaction that includes forward-looking statements regarding their business outlook, specifically for the fiscal year 2024. The presentation warns investors about the uncertainties tied to their ability to achieve sustainable profits and discusses the reliance on their NeuroStar Advanced Therapy System for revenue. While the acquisition may enhance brand awareness and operational capabilities, it poses several risks, including dependency on a small customer base and potential management distractions. Detailed investor documentation is forthcoming and available through appropriate channels.
Read more →STIM▲ +12.3%on this news· ran to +37% by day 3shared move
Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about
Neuronetics, Inc. has received FDA clearance for its NeuroStar Advanced Therapy System as an add-on treatment for individuals aged 15 and older. The company highlights the vast market potential within the U.S. TMS market, suggesting a growing demand for its products. Nonetheless, Neuronetics cautions investors about the inherent risks in its forward-looking statements, including reliance on a limited customer base and uncertainties regarding financial projections. The transaction with Greenbrook, which is currently in progress, also poses potential challenges, including stockholder approvals and management disruptions.
Read more →STIM▼ -58.1%on this newsshared move
Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
Neuronetics, Inc. is set to acquire Greenbrook TMS Inc. in an all-stock transaction as part of a definitive agreement aimed at consolidating their resources in the mental health space. This merger will create a vertically-integrated organization that can enhance the delivery of TMS therapy and improve operational efficiencies. The combined company is projected to have a revenue of approximately $145 million in fiscal year 2023, leveraging substantial cost synergies and increasing the growth trajectory for the new entity. As part of the acquisition, Greenbrook's debt will be converted into shares, and key leadership from both companies will be retained to steer the new organization forward.
Read more →STIM▼ -58.1%on this newsshared move
Presentation Operator Good day, and thank you for standing by. Welcome to the Neuronetics Second Quarter 2024 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that today s confer
Neuronetics has reported its second quarter 2024 financial results, indicating a 7% decline in revenue to $16.5 million amid challenges such as a cybersecurity breach affecting Change Healthcare. CEO Keith Sullivan highlighted a recovery in treatment session utilization and positive trends in the Better Me program for improved patient follow-up. Despite recognizing strong demand for its NeuroStar systems, the company faced constraints in revenue growth due to delay in payments and financing issues. The launch of adolescent TMS therapy and an upcoming advertising campaign in Tampa aim to bolster patient awareness and access to treatment.
Read more →STIM▼ -58.1%on this newsshared move
Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. reported its financial and operating results for the second quarter of 2024, highlighting record achievements despite facing industry challenges. The company has received FDA clearance for its NeuroStar therapy in adolescents, and major insurers have expanded coverage for this treatment. However, Neuronetics experienced a 7% decline in total revenues, primarily due to decreased treatment sessions and sales. Additionally, a planned merger with Greenbrook TMS is anticipated to enhance the company's market position and financial stability.
Read more →STIMNeuronetics to Present at the Canaccord Genuity 44th Annual Growth Conference
Neuronetics, Inc. will present at the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024. The presentation will focus on its NeuroStar Advanced Therapy, a non-invasive treatment for neurohealth disorders, particularly Major Depressive Disorder. The therapy has reached significant usage, with over 6.4 million treatments, and aims to redefine mental health expectations. A live audio webcast of the presentation will be accessible via the company's investor relations page.
Read more →STIMNeuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors MALVERN, Pa.
Neuronetics, Inc. has secured a senior secured credit facility of up to $90 million from Perceptive Advisors, receiving an initial $50 million tranche. This funding will be used to repay an existing loan and bolster Neuronetics' financial position while supporting its commercial and clinical initiatives, particularly the NeuroStar Advanced Therapy for mental health. Subsequent funding tranches will be available upon achieving specific milestones, enhancing the company's growth prospects in the neurohealth sector.
Read more →STIMNeuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. plans to release its financial and operating results for the second quarter of 2024 on August 12th, prior to the market opening. Following the release, a conference call will take place at 8:30 a.m. Eastern Time to discuss these results. The company focuses on neurohealth disorders and has established itself as a leader in non-invasive treatments like NeuroStar, which is FDA-cleared for multiple conditions. Neuronetics aims to redefine outcomes in mental health treatment through its advanced technologies.
Read more →STIM▲ +6.3%on this news· ran to +17% by day 1
William Blair th 44 Annual Growth Stock Conference
Neuronetics, Inc. provided insights during the William Blair 44th Annual Growth Stock Conference, emphasizing their positive expectations for upcoming quarters and fiscal year 2024. The company reported record results in the first quarter and highlighted the success of their Better Me Provider Program, which has improved patient response times significantly. However, they acknowledged ongoing risks related to profitability and their reliance on a small customer base for revenue generation. Additionally, there are uncertainties surrounding the execution of their business strategy.
Read more →STIMNeuronetics to Present at the William Blair 44th Annual Growth Stock Conference
Neuronetics, Inc. announced that its management team will present at the William Blair 44th Annual Growth Stock Conference on June 6, 2024. The presentation will focus on their innovations in neurohealth, particularly the NeuroStar Advanced Therapy for treating mental health disorders. NeuroStar is described as an effective non-invasive treatment option for patients with major depressive disorder (MDD) and anxiety symptoms. The company emphasizes its commitment to enhancing patient outcomes through advanced therapeutic solutions.
Read more →STIM▼ -30.7%on this news
Neuronetics Reports Record First Quarter 2024 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. reported strong first quarter 2024 results, with total revenues increasing by 12% to $17.4 million compared to the previous year. The company achieved a significant regulatory milestone with FDA clearance for its NeuroStar treatment as a first-line adjunct therapy for adolescent major depressive disorder, increasing its market potential by 35%. Despite the positive revenue growth, the company experienced a decrease in revenue from the NeuroStar Advanced Therapy System and reported a net loss of $7.9 million. Neuronetics continues to expand its operations, including a new partnership with Transformations Care Network to enhance treatment availability.
Read more →STIMNeuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. (NASDAQ: STIM) will announce its first quarter 2024 financial and operating results on May 7, 2024, prior to market opening. The company plans to hold a conference call at 8:30 a.m. Eastern Time to discuss these results with stakeholders. Neuronetics is known for its NeuroStar Advanced Therapy, a non-invasive treatment for mental health conditions that has delivered over 6.1 million treatments. The therapy is FDA-cleared for various conditions, establishing Neuronetics as a significant player in the neurohealth sector.
Read more →STIMNeuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
Neuronetics, Inc. has announced a five-year exclusive partnership with Transformations Care Network to supply the NeuroStar TMS equipment, increasing its availability to patients. This collaboration aims to address the growing need for mental health services, particularly for those affected by major depressive disorder. Transformations Care Network's commitment to integrating advanced treatment options reflects a progressive approach to mental health care. The partnership enhances care quality and acknowledges the challenges of treatment-resistant depression.
Read more →STIM▲ +15.4%on this news· ran to +48% by day 3shared move
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. reported record financial results for Q4 and the full year 2023, with total revenues increasing by 12% compared to the previous year. The company achieved a significant milestone by generating positive cash flow for the first time in its history. However, international revenue saw a notable decrease of 35% in the fourth quarter, impacting the overall performance. The company is optimistic about growth, particularly through its newly launched Better Me Guarantee Provider pilot program.
Read more →STIMNeuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. (NASDAQ: STIM) will announce its fourth quarter 2023 financial and operating results on March 5th, 2024, prior to market opening. A conference call to discuss these results will take place at 8:30 a.m. Eastern Time the same day. The company is known for its NeuroStar Advanced Therapy for mental health, offering non-invasive treatment options for neurohealth disorders. This therapy has become a leading solution for major depressive disorder, with substantial clinical backing.
Read more →STIMNeuronetics Launches Latest Evolution in its TrakStar Patient Data Management System
Neuronetics, Inc. has announced significant enhancements to its TrakStar Patient Data Management System, aimed at improving patient management for neurohealth treatments. The updated system includes new features that streamline tracking of patient status and facilitate better internal communication for healthcare providers. Key enhancements also provide practices with pre-treatment financial responsibility estimates, enhancing patient clarity during consultations. These updates are available now for all cloud-based NeuroStar providers.
Read more →STIM▼ -6.4%on this news
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results MALVERN, PA.
Neuronetics, Inc. reported its preliminary financial results for the fourth quarter and fiscal year 2023, expecting total revenues to surpass $20 million, achieving a record in U.S. Treatment Session revenue. The company also experienced significant growth in local consumable revenue and positive cash flow, marking a strong year-end. CEO Keith J. Sullivan expressed enthusiasm for expanding NeuroStar's use and highlighted the upcoming Better Me Guarantee Provider pilot program as a key initiative for 2024. Despite these positives, the company faces potential risks including revenue recognition issues and its reliance on NeuroStar sales.
Read more →STIMNeuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
Neuronetics, Inc. has received FDA 510(k) clearance for its NeuroSite™ Coil Placement Accessory, enhancing the NeuroStar TMS treatment process. This innovative tool simplifies coil positioning and measurement, improving efficiency and patient experience. It is designed to work with both existing and new NeuroStar systems, set to be available to providers in Q1 2024. The company emphasizes its commitment to improving mental health treatment through advanced technology.
Read more →STIMNeuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference
Neuronetics, Inc. will present at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 2:00 PM ET. The presentation will be available via a live audio webcast on the company's investor relations page. Neuronetics is known for its NeuroStar Advanced Therapy, a noninvasive treatment for neurohealth disorders, including major depressive disorder. The company aims to redefine expectations in mental health care through its innovative solutions.
Read more →STIM▼ -11.3%on this news
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
Neuronetics, Inc. announced significant updates on TMS therapy coverage from major health plans, including Magellan and BlueCross BlueShield of Kansas City, which aim to improve access to NeuroStar Advanced Therapy for patients with major depressive disorder. The updated policies reduce the required antidepressant medication failures from four to two and eliminate previous psychotherapy trial requirements. Effective immediately, these changes represent a pivotal move toward enhancing mental health treatment accessibility amid a growing crisis. The announcement reflects Neuronetics' commitment to transforming mental health care and providing innovative, non-drug treatments for depression.
Read more →STIM▲ +8.1%on this newsshared move
Neuronetics Reports Third Quarter 2023 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. has reported its financial results for the third quarter of 2023, showing an 8% increase in total revenue compared to the same quarter last year. The company experienced significant growth in international markets, driven primarily by NeuroStar Advanced Therapy system sales. Key highlights include a record increase in treatment session revenue and the launch of the Better Me Guarantee Provider program. Despite these positives, the company reported a net loss that has widened from the previous year, alongside a decrease in gross margin due to inventory impairments.
Read more →STIMNeuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. (NASDAQ: STIM) announced it will report its third quarter 2023 financial and operating results on November 7, 2023, before market opening. Following the release, the company will host a conference call at 8:30 a.m. Eastern Time to discuss the results. Neuronetics is known for its NeuroStar Advanced Therapy, a noninvasive treatment for neurohealth disorders that has seen significant adoption with over 5.6 million treatments delivered. This highlights the company's commitment to improving mental health care.
Read more →STIM▼ -6.9%on this news
Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility MALVERN, Pa.
Neuronetics, Inc. has drawn down the remaining $22.5 million from its credit facility with SLR Capital Partners. This move is intended to strengthen the company's balance sheet and support its ongoing business strategy in a challenging capital markets environment. The company is optimistic about achieving cash flow break-even in late 2024. Additionally, improvements in mental health therapy promise further adoption of its NeuroStar Advanced Therapy system, which is a leading non-invasive treatment platform.
Read more →STIMNeuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar Platform
Neuronetics, Inc. has announced significant enhancements to its TrakStar Patient Data Management System, aimed at improving communication and support for providers. The updates include automated features such as SMS text messaging and a customizable patient dashboard, designed to streamline patient management in NeuroStar transcranial magnetic stimulation (TMS) treatment. These enhancements are part of Neuronetics' ongoing commitment to elevate patient care and support clinical practices. Available now for cloud-based NeuroStar providers, these innovations aim to redefine expectations in mental health treatment.
Read more →STIMNeuronetics Reports Record Second Quarter 2023 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. reported record financial results for the second quarter of 2023, with total revenues reaching $17.6 million, reflecting an 8% year-over-year growth. The company saw significant international revenue growth of 63%, driven largely by increased NeuroStar Advanced Therapy system sales. Despite a decrease in gross margin, the net loss improved significantly from the previous year. Additionally, Neuronetics received FDA clearance for new OCD treatment technology, enhancing their product offerings.
Read more →STIMNeuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. (NASDAQ: STIM) announced its plans to report second quarter 2023 financial and operating results on August 8, 2023, before market open. Following the release, the company will host a conference call at 8:30 a.m. Eastern Time to discuss the results. Neuronetics is known for its NeuroStar Advanced Therapy, a non-invasive treatment for mental health conditions, including major depressive disorder and obsessive-compulsive disorder. The company emphasizes its commitment to enhancing the quality of life for patients suffering from neurohealth disorders.
Read more →STIMNeuronetics Announces Expanded TMS Therapy Access Through Aetna Health Plans
Neuronetics, Inc. has announced that Aetna will now allow transcranial magnetic stimulation (TMS) treatment for major depressive disorder to be ordered by behavioral health nurse practitioners, thereby increasing patient access. Notably, the requirement for a four-month psychotherapy trial has been removed, enabling quicker initiation of treatment for those in need. This represents a significant policy update as Aetna is one of the largest health plans in the U.S., covering over 16.8 million lives. The move reflects a broader trend among insurers to improve access to mental health treatments.
Read more →STIMNeuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
Neuronetics, Inc. has announced that it received 510(k) clearance from the FDA for its OCD Motor Threshold (MT) Cap technology for the NeuroStar Advanced Therapy. This innovation aims to improve treatment efficiency by simplifying the process of determining a patient’s Motor Threshold, thus optimizing care for obsessive-compulsive disorder. The OCD MT Cap will be available at select sites starting this month, with nationwide availability expected later in the year. The new cap, like its predecessor for major depressive disorder, offers significant time savings during initial patient visits.
Read more →STIM▲ +6.2%on this news
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan
Neuronetics, Inc. announced an important policy update from BlueCross BlueShield of Michigan that expands access to transcranial magnetic stimulation (TMS) for patients with major depressive disorder. This update reduces the required number of antidepressant trials prior to TMS eligibility from four to two, potentially improving treatment access for many patients. The change reflects a broader trend among health payers to enhance coverage for mental health treatments, addressing the growing need in light of the shortage of mental healthcare providers.
Read more →STIMNeuronetics to Present at the William Blair 43rd Annual Growth Stock Conference
Neuronetics, Inc. will present at the William Blair 43rd Annual Growth Stock Conference on June 7, 2023. The presentation will be available via webcast, allowing broad investor access. The company focuses on innovative neurohealth therapies, particularly its FDA-cleared NeuroStar system for treating depression and other psychiatric disorders. With a commitment to improving mental health care, Neuronetics is recognized as a leader in the TMS industry.
Read more →STIMNeuronetics Wins 2023 Bell Seal for Workplace Mental Health
Neuronetics, Inc. has been awarded the Silver Bell Seal for Workplace Mental Health by Mental Health America, recognizing its dedication to fostering a supportive workplace culture. The company's emphasis on employee well-being aligns with its mission to improve lives through its innovative NeuroStar Advanced Therapy for Mental Health. This non-drug treatment offers significant benefits for individuals suffering from medication-resistant depression. The recognition underscores the company's commitment to creating a psychologically safe environment for its employees and patients alike.
Read more →STIM▲ +27.3%on this news
Neuronetics Reports Record First Quarter 2023 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. reported a record revenue of $15.5 million for the first quarter of 2023, marking a 10% increase from the prior year. The company attributed this growth to increased sales of its NeuroStar treatment sessions and improvements in healthcare access policies. However, international revenues fell by 13%, and the company continues to report a significant net loss. Neuronetics has secured a $60 million debt financing facility to enhance its commercial operations and has made advancements in technology and patient access through new policy updates and FDA approvals.
Read more →STIM▲ +27.3%on this news
Neuronetics to Present at the JMP Securities Life Sciences Conference
Neuronetics, Inc. (NASDAQ: STIM) will present at the JMP Securities Life Sciences Conference on May 16, 2023, with CEO Keith Sullivan and CFO Steve Furlong. The presentation will highlight their role as a leader in neurohealth therapies, specifically their NeuroStar Advanced Therapy system, which is FDA-cleared for depression and other psychiatric disorders. A live webcast of the presentation will be available, and a replay will be archived for approximately 90 days.
Read more →STIMNeuronetics Receives MDSAP Certification and CE Mark Certification under New MDR
Neuronetics, Inc. has received CE Mark Certification and MDSAP certification, enhancing its compliance with international regulatory standards. The CE Mark allows the company to market its NeuroStar Advanced Therapy in the European Union under rigorous safety and effectiveness requirements. The MDSAP certification streamlines the audit process for multiple countries, including the U.S. and Japan, positioning Neuronetics for broader distribution. This move represents a significant step in the company's commitment to patient care and regulatory excellence.
Read more →STIMNeuronetics Showcases New NeuroStar TMS Findings at Clinical TMS Society Annual Meeting
Neuronetics, Inc. is actively participating as a Gold Sponsor at the Clinical TMS Society Annual Meeting from May 4-6, 2023, in Colorado Springs, CO. The company will present data from the NeuroStar Outcomes Registry, highlighting results from over 7,000 patients with major depressive disorder (MDD). Notable sessions will include discussions on treatment completion, tapering TMS treatment, and the effectiveness of re-treatment. NeuroStar is recognized as the leading non-invasive treatment for MDD, emphasizing its commitment to redefining mental health care.
Read more →STIMNeuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
Neuronetics, Inc. has appointed Lisa Metzner-Rosas as Senior Vice President and Chief Marketing Officer, effective May 1, 2023. With over 20 years of experience in healthcare marketing, she has a solid track record of enhancing market share and driving sales growth. Her previous role at Sientra saw her lead a successful global commercial strategy, and she aims to further the growth of Neuronetics and strengthen its NeuroStar brand. The company is known for its innovative non-invasive treatments for mental health disorders.
Read more →STIMNeuronetics Announces Expanded TMS Access through United HealthCare
Neuronetics, Inc. has announced an expansion of access to its NeuroStar Advanced Therapy for Mental Health through updated Medicare Advantage policies by United HealthCare. The policy change allows nurse practitioners to order and administer TMS therapy for patients suffering from major depressive disorder in certain states. This expansion builds on Neuronetics' previous updates to United HealthCare's commercial policy, which has already increased access for millions of covered lives. The company emphasizes its commitment to improving mental health care through strong partnerships with providers and payers.
Read more →STIMNeuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. is preparing to report its financial and operating results for Q1 2023 on May 9th, 2023, ahead of market opening. The company will also host a conference call to discuss the results, highlighting its innovative mental health treatment, NeuroStar. This non-invasive therapy is FDA-cleared for various conditions and has delivered over 5.3 million treatments. Neuronetics aims to enhance the quality of life for patients suffering from neurohealth disorders through its leading technology.
Read more →STIMNeuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
Neuronetics, Inc. announced that BlueCross BlueShield of Mississippi has updated its healthcare policy to allow more healthcare professionals to administer transcranial magnetic stimulation (TMS) therapy for major depressive disorder. This update, which reduces the required number of prior medication attempts, aims to enhance patient access to the NeuroStar® Advanced Therapy. The policy change reflects a broader trend among payers to increase mental health coverage, reinforcing Neuronetics' commitment to improving treatment options for those suffering from depression.
Read more →STIMNeuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note MALVERN, Pa.
Neuronetics has successfully entered a new credit facility with SLR Capital Partners, securing up to $60 million in debt financing which will enhance the company's balance sheet. This financing includes three tranches of loans with a maturity date of March 29, 2028. Additionally, Neuronetics has converted outstanding payables into a $6 million promissory note for Greenbrook TMS, demonstrating their ongoing partnership in advancing TMS therapies for mental health treatment. The company aims to boost commercial adoption while seeking cash flow breakeven in 2024.
Read more →STIM▼ -19.2%on this news· ran to -39% by day 3
Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results MALVERN, PA.
Neuronetics, Inc. announced its financial results for the fourth quarter and full year of 2022, reporting a 21% increase in total revenues for Q4 2022. Notably, the company achieved a 64% year-over-year growth in U.S. NeuroStar System revenue. However, a net loss of $(8.3) million in Q4 2022 was recorded, compared to $(7.6) million in the same quarter of 2021, alongside a decrease in gross margin. Despite challenges such as increased operating expenses, the company remains focused on strategic growth initiatives aimed at achieving cash flow breakeven by 2024.
Read more →STIM▼ -5.3%on this news· ran to -24% by day 3shared move
Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
Neuronetics announced changes in TMS coverage criteria by United HealthCare, reducing the required prior medication failures from four to two and eliminating the psychotherapy trial requirement. This update is significant as it increases treatment access for over 23 million covered lives suffering from depression. The changes reflect a positive shift in healthcare payer response to the need for improved mental health treatments. Neuronetics continues to position itself as a leader in TMS therapy with ongoing advocacy for health policy changes.
Read more →STIM▼ -10%on this newsshared move
Neuronetics Expands NeuroStar Advanced Therapy’s Proprietary TrakStar Platform
Neuronetics, Inc. has announced the launch of its new TrakStar software enhancements and an educational campaign aimed at improving patient management for NeuroStar providers. The updates include features for benefits investigation and automated health questionnaires, streamlining the treatment process for patients. This initiative is part of Neuronetics' broader commitment to enhancing mental health care through innovative technology. TrakStar is designed to support NeuroStar transcranial magnetic stimulation practices, which are recognized for treating major depressive disorder and related conditions.
Read more →STIMNeuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. has announced plans to release its fourth quarter 2022 financial and operating results on March 7, 2023. A conference call will be held at 8:30 a.m. Eastern Time to discuss these results, which will be accessible to participants via webcast. The company continues to promote its NeuroStar Advanced Therapy for Mental Health, highlighting its non-invasive approach and significant clinical data.
Read more →STIMNeuronetics Sponsors the 5th International Brain Stimulation Conference
Neuronetics, Inc. announced its participation as a Silver Sponsor at the 5th International Brain Stimulation Conference in Lisbon, where it will present new research findings on the NeuroStar Advanced Therapy. Dr. Harold Sackeim will showcase data indicating a strong correlation between the number of transcranial magnetic stimulation (TMS) treatment sessions and improved depression outcomes. The study, based on over 7,000 patients, emphasizes the importance of completing prescribed treatment courses for optimal results in managing major depressive disorder (MDD). The findings aim to support physicians in delivering effective neurohealth treatments.
Read more →STIMNeuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
Neuronetics, Inc. has promoted Sara Grubbs to Senior Vice President and Chief Revenue Officer, effective immediately. Grubbs, who has served as Vice President of Sales since 2020, will continue to oversee sales functions while expanding her responsibilities to additional revenue-related areas. Under her leadership, Neuronetics has significantly increased its NeuroStar Advanced Therapy footprint, boosting sales productivity and establishing key strategic partnerships. The promotion is part of Neuronetics' long-term strategy to enhance growth and integrate their revenue cycle effectively.
Read more →STIMNeuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
Neuronetics, Inc. has announced an updated Medicare policy from National Government Services that expands access to its NeuroStar TMS therapy for patients suffering from major depressive disorder. Effective April 1, 2023, the policy allows nurse practitioners to order and provide TMS treatments, thereby enhancing patient access to this non-drug therapy. Additionally, the medication requirement for TMS eligibility has been reduced, facilitating more patients receiving care. Neuronetics highlights the importance of these changes amidst a nationwide mental health crisis.
Read more →STIMNeuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
Neuronetics and Greenbrook TMS have announced a six-year exclusive partnership, making Neuronetics the sole supplier of TMS equipment to Greenbrook. This agreement aims to enhance patient and clinician awareness, improve access to care, and advance the development of TMS therapies for mental health disorders. The partnership includes minimum purchase commitments and a new 'per-click' consumable model for treatment sessions. Both companies express optimism about the potential growth and impact of TMS treatments on patient care.
Read more →STIMNeuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar Advanced Therapy for Mental Health
Neuronetics, Inc. announced a peer-reviewed publication confirming the efficacy of NeuroStar Advanced Therapy for treating anxious depression. This study analyzed data from over 1,800 patients and demonstrated significant improvements in both anxiety and depression symptoms. The findings underline the effectiveness of NeuroStar in addressing comorbid conditions and are backed by the largest depression outcomes registry. Additionally, NeuroStar received FDA clearance to treat anxious depression, further establishing its role in enhancing patient care.
Read more →STIMNeuronetics Settles Litigation Against BrainsWay
Neuronetics, Inc. has announced the settlement of litigation against BrainsWay for unfair competition related to the efficacy data of their NeuroStar Advanced Therapy for Mental Health. Under the settlement, BrainsWay will cease using certain efficacy data concerning treatment for anxious depression. The terms of the settlement remain confidential, but Neuronetics emphasizes its commitment to defending its efficacy claims. NeuroStar is recognized as a leading treatment for major depressive disorder and has delivered over 5 million treatments to date.
Read more →STIMNeuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results MALVERN, Pa.
Neuronetics, Inc. reported preliminary fourth quarter and full year 2022 financial results, indicating revenues of approximately $18.0 million for the fourth quarter and $65.0 million for the full year. This surpassed previous guidance and reflects the company’s effective marketing strategies and execution of its business model. The company anticipates continued momentum into 2023 as it aims to expand access to its NeuroStar Advanced Therapy for patients suffering from mental health disorders. Neuronetics emphasizes the importance of mental health and positions itself as a leader in non-invasive treatment solutions.
Read more →STIMNeuronetics Announces Appointment of Joseph H. Capper to its Board of Directors
MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, tod
Read more →STIMNeuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
MALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is named a
Read more →STIM▼ -6.2%on this news
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today annou
Read more →STIMNeuronetics Announces NeuroStar Advanced Therapy for Mental Health System Innovations
MALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced
Read more →STIMNeuronetics Reports Third Quarter 2022 Financial and Operating Results MALVERN, PA.
Neuronetics Reports Third Quarter 2022 Financial and Operating Results MALVERN, PA., November 8, 2022 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need h
Read more →STIMNeuronetics Announced as Winner by 2022 Merit Awards for Technology
MALVERN, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is named
Read more →STIMNeuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced
Read more →STIMNeuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today anno
Read more →STIMNeuronetics Launches Innovations To NeuroStar Advanced Therapy’s Proprietary TrakStar Platform
MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announce
Read more →STIMNeuronetics, Inc. Announces Grand Opening of NeuroStar University with Ribbon-Cutting Ceremony
MALVERN, Pa., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced
Read more →STIM▼ -6.5%on this news
Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar Advanced Therapy for Mental Health
MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced
Read more →STIMNeuronetics Reports Second Quarter 2022 Financial and Operating Results MALVERN, PA.
Neuronetics Reports Second Quarter 2022 Financial and Operating Results MALVERN, PA., August 2, 2022 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need he
Read more →STIMNeuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference
MALVERN, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, to
Read more →STIMNeuronetics and Alleviant Health Centers Announce Exclusive Partnership
Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients MALVERN, Pa., July 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketin
Read more →STIMNeuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today anno
Read more →STIM▲ +5.7%on this news
Neuronetics Recognized as Top Non-Invasive Devices Provider in 2022
MALVERN, Pa., July 13, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, including
Read more →STIMNeuronetics Announces Positive TMS Coverage Policies to Expand Patient Access to NeuroStar TMS Therapy for Mental Health
MALVERN, Pa., July 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today
Read more →STIMNeuronetics to Present at the William Blair 42nd Annual Growth Stock Conference
MALVERN, Pa., May 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, tod
Read more →STIM▲ +8.1%on this news· ran to +23% by day 1
Neuronetics Reports First Quarter 2022 Financial and Operating Results MALVERN, PA.
Neuronetics Reports First Quarter 2022 Financial and Operating Results MALVERN, PA., May 12, 2022 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it wi
Read more →STIM▼ -11.4%on this newsshared move
Neuronetics and Transformations Care Network Announce Extended Commercial Partnership
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today
Read more →STIM▼ -11.4%on this newsshared move
Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, ann
Read more →STIM▼ -11.4%on this newsshared move
Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today annou
Read more →STIMNeuronetics to Report First Quarter 2022 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today ann
Read more →STIMNeuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results MALVERN, PA.
Neuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results MALVERN, PA., March 8, 2022 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever
Read more →STIMNeuronetics to Report Fourth Quarter and Fiscal Year 2021 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today anno
Read more →STIMNeuronetics Announces Amendment of Credit Facility with SLR Investment Corp. MALVERN, Pa.
Neuronetics Announces Amendment of Credit Facility with SLR Investment Corp. MALVERN, Pa., February 22, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve
Read more →STIM▲ +14.9%on this news
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results MALVERN, Pa.
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results MALVERN, Pa., January 10, 2022 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the qualit
Read more →STIMNeuronetics Announces 510(k) Clearance of MT Cap Technology for NeuroStar Advanced Therapy for Mental Health
MALVERN, Pa., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced
Read more →STIMNeuronetics Announces Key Role for NeuroStar Advanced Therapy at 4th International Brain Stimulation Conference
MALVERN, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced
Read more →STIMNeuronetics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
MALVERN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today annou
Read more →STIMNeuronetics Reports Third Quarter 2021 Financial and Operating Results MALVERN, PA.
Neuronetics Reports Third Quarter 2021 Financial and Operating Results MALVERN, PA., November 9, 2021- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for pat
Read more →STIMNeuronetics and River Region Psychiatry Announce Exclusive Partnership
Partnership Will Bring Non-drug NeuroStar® Advanced Therapy For Mental Health To Thousands of Patients Across the Southeast MALVERN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, devel
Read more →STIMNeuronetics to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today annou
Read more →STIMNeuronetics Celebrates 235,000 Treatment Milestone for Success TMS
MALVERN, Pa., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced
Read more →STIMCORRECTION - Neuronetics Announces Preliminary Revenue for Third Quarter 2021 Malvern, PA
For a discussion of these and other related risks, please refer to the Company's recent SEC filings which are available on the SEC's website at www.sec.gov. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press relea
Read more →STIMNeuronetics Launches Upgrades of NeuroStar Advanced Therapy for Mental Health
System Innovations Improve Efficiencies for Healthcare Practices and Patients MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the
Read more →STIMNeuronetics Announces Preliminary Revenue for Third Quarter 2021 MALVERN, Pa.
NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extrao
Read more →STIMNeuronetics Announces Commercial Agreement with Success TMS
MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today annou
Read more →STIMNeuronetics and Zion Healing Announce First Franchise Model for TMS Clinics
MALVERN, Pa. and ST. GEORGE, Utah, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth
Read more →STIM▼ -10.3%on this news
Neuronetics Launches New Website to Meet Patient Demand for Depression Resources
MALVERN, Pa., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced i
Read more →STIM▲ +12.4%on this news
Neuronetics Announces Appointment of Megan Rosengarten to its Board of Directors MALVERN, Pa.
Neuronetics Announces Appointment of Megan Rosengarten to its Board of Directors MALVERN, Pa., August 05, 2021 (GLOBE NEWSWIRE) Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve
Read more →STIM▼ -42%on this newsshared move
Neuronetics Reports Second Quarter 2021 Financial and Operating Results MALVERN, PA.
Neuronetics Reports Second Quarter 2021 Financial and Operating Results MALVERN, PA., August 3, 2021- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for pati
Read more →STIMNeuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference
MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Launches Enhanced Digital Resource Center for NeuroStar Providers
MALVERN, Pa., July 14, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced t
Read more →STIMNeuronetics Set to Join Russell 2000 Index
MALVERN, Pa., June 23, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting
MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced t
Read more →STIMNeuronetics to Present at The JMP Securities Life Sciences Conference
MALVERN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Names Todd Cushman as Vice President, Business Development
MALVERN, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced t
Read more →STIMNeuronetics to Present at the William Blair 41st Annual Growth Stock Conference
MALVERN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics Celebrates 100,000 Treatment Milestone for Southern California TMS Center
MALVERN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders announced tod
Read more →STIMNeuronetics Reports First Quarter 2021 Financial and Operating Results MALVERN, PA.
Neuronetics Reports First Quarter 2021 Financial and Operating Results MALVERN, PA., May 04, 2021- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patient
Read more →STIMNeuronetics Employee Patient Advocates Honor Mental Health Awareness Month by Sharing Personal Depression Experiences
MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, is honoring
Read more →STIMNeuronetics To Present Clinical Data at The American Psychiatric Association 2021 Annual Meeting
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced
Read more →STIMNeuronetics to Report First Quarter 2021 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today anno
Read more →STIMNeuronetics Announces Retirement of Brian Farley and Appointment of Robert Cascella as Chairman of its Board of Directors MALVERN, Pa.
Neuronetics Announces Retirement of Brian Farley and Appointment of Robert Cascella as Chairman of its Board of Directors MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developi
Read more →STIMNeuronetics Announces Appointment of Robert Cascella to its Board of Directors MALVERN, Pa., April 1st, 2021 (GLOBE NEWSWIRE) Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on des
Neuronetics Announces Appointment of Robert Cascella to its Board of Directors MALVERN, Pa., April 1st, 2021 (GLOBE NEWSWIRE) Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the
Read more →STIMNeuronetics Announces Retirement of Gregory Harper, Vice President, R&D and Clinical
MALVERN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today ann
Read more →STIMNeuronetics Enhances TrakStar Cloud Patient Data Management System to Maximize Physician Efficiencies
MALVERN, Pa., March 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today anno
Read more →STIMNeuronetics Names Cory Anderson Vice President, Clinical Affairs and Medical Operations
MALVERN, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today anno
Read more →STIMNeuronetics Reports Fourth Quarter and Full Year 2020 Financial and Operating Results MALVERN, PA.
Neuronetics Reports Fourth Quarter and Full Year 2020 Financial and Operating Results MALVERN, PA., March 02, 2021- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of
Read more →STIMNeuronetics to Report Fourth Quarter and Fiscal Year 2020 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Announces Strategic Leadership Promotions to Support Future Growth
MALVERN, Pa., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced t
Read more →STIMNeuronetics to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
MALVERN, Pa., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disord
Read more →STIMNeuronetics Announces Pricing of $75 Million Public Offering of Common Stock
MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disord
Read more →STIMDisclaimers This presentation has been prepared solely for use at this meeting. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise
Neuronetics, Inc. NASDAQ: STIM Company Presentation January 2021 Exhibit 99.1 Disclaimers This presentation has been prepared solely for use at this meeting. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the conte
Read more →STIMNeuronetics Announces Proposed Public Offering of Common Stock
MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disord
Read more →STIMNeuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results MALVERN, Pa.
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results MALVERN, Pa., January 12, 2021 Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality
Read more →STIMNeuronetics to Participate at the 23rd Annual ICR Westwicke Conference
MALVERN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Announces Expansion of Sales Organization
MALVERN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Announces the Amendment of Credit Facility with Solar Capital Partners Amendment provides Neuronetics with available and flexible funding options through 2022 MALVERN, Pa.
Neuronetics Announces the Amendment of Credit Facility with Solar Capital Partners Amendment provides Neuronetics with available and flexible funding options through 2022 MALVERN, Pa., December 8, 2020 Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology com
Read more →STIMNeuronetics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Receives FDA Clearance for Three-Minute TouchStar™ Treatment Protocol
MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced t
Read more →STIMNeuronetics to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
MALVERN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Reports Third Quarter 2020 Financial and Operating Results MALVERN, Pa.
Neuronetics Reports Third Quarter 2020 Financial and Operating Results MALVERN, Pa., November 02, 2020 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for p
Read more →STIMNeuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Appoints Sara Grubbs as Vice President, Sales
MALVERN, Pa., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric disorders, announced that Sara Grubbs has been appointed as the company’s Vice Pr
Read more →STIMNeuronetics Celebrates 500,000 Treatment Milestone for Greenbrook TMS
MALVERN, Pa., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today cong
Read more →STIMNeuronetics Unveils New Depression Data at Clinical TMS Society’s Virtual Events
MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, will prese
Read more →STIMNeuronetics Reports Second Quarter 2020 Financial and Operating Results MALVERN, Pa.
Neuronetics Reports Second Quarter 2020 Financial and Operating Results MALVERN, Pa., August 04, 2020 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for pa
Read more →STIMNeuronetics to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer MALVERN, Pa.
Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer MALVERN, Pa., July 14, 2020 (GLOBE NEWSWIRE) Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer
Read more →STIMNeuronetics Announces Appointment of Bruce J. Shook to its Board of Directors MALVERN, Pa.
Neuronetics Announces Appointment of Bruce J. Shook to its Board of Directors MALVERN, Pa., June 26, 2020 (GLOBE NEWSWIRE) Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the qu
Read more →STIMNeuronetics to Present at the William Blair 40th Annual Growth Stock Conference
MALVERN, Pa., June 04, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics, Inc. Announces Virtual 2020 Annual Meeting of Stockholders
MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (Nasdaq: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics Recognizes Critical Health Professionals During Mental Health Awareness Month
MALVERN, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, is celebrati
Read more →STIMNeuronetics Reports First Quarter 2020 Financial and Operating Results MALVERN, Pa.
Neuronetics Reports First Quarter 2020 Financial and Operating Results MALVERN, Pa., May 05, 2020 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patien
Read more →STIMNeuronetics to Report First Quarter 2020 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 21, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today anno
Read more →STIMNeuronetics, Inc. Adopts Limited Duration Shareholder Rights Plan MALVERN, Pa.
Neuronetics, Inc. Adopts Limited Duration Shareholder Rights Plan MALVERN, Pa., April 8, 2020 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients w
Read more →STIMNeuronetics, Inc. Announces Preliminary First Quarter 2020 Revenue, Corporate Restructuring, and Provides Business Update MALVERN, Pa.
Neuronetics, Inc. Announces Preliminary First Quarter 2020 Revenue, Corporate Restructuring, and Provides Business Update MALVERN, Pa., Apr 8, 2020 (GLOBE NEWSWIRE) Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing
Read more →STIMNeuronetics Recognized as 2020 Top Neurology Device Provider
Company acknowledged on Top 10 List by MedTech Outlook Magazine MALVERN, Pa., March 30, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of li
Read more →STIMNeuronetics Hits Major Milestones with More Than 2.5 Million Treatments and 1,000 Installations of Its NeuroStar Advanced Therapy System
MALVERN, Pa., March 16, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today anno
Read more →STIMNeuronetics, Inc. announces Chris Thatcher will step down as President and
Neuronetics, Inc. announces Chris Thatcher will step down as President and CEO MALVERN, Pa., March 5, 2020 Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life fo
Read more →STIMNeuronetics Reports Fourth Quarter and Full Year 2019 Financial and Operating Results MALVERN, Pa.
Neuronetics Reports Fourth Quarter and Full Year 2019 Financial and Operating Results MALVERN, Pa., March 03, 2020 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality o
Read more →STIMNeuronetics to Report Fourth Quarter and Fiscal Year 2019 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Appoints Andrew Macan As Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
MALVERN, Pa., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics to Present at the 31st Annual Piper Jaffray Healthcare Conference
MALVERN, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics Reports Third Quarter 2019 Financial and Operating Results MALVERN, Pa.
Neuronetics Reports Third Quarter 2019 Financial and Operating Results MALVERN, Pa., November 05, 2019 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for p
Read more →STIMNeuronetics Announces Appointment of Sheryl Conley to its Board of Directors MALVERN, Pa.
Neuronetics Announces Appointment of Sheryl Conley to its Board of Directors MALVERN, Pa., November 1, 2019 Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life
Read more →STIMNeuronetics to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Reports Second Quarter 2019 Financial and Operating Results MALVERN, Pa.
Neuronetics Reports Second Quarter 2019 Financial and Operating Results MALVERN, Pa., August 06, 2019 - Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for pa
Read more →STIMNeuronetics to Present at the 39th Annual Canaccord Genuity Growth Conference
MALVERN, Pa., July 25, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 23, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Appoints Stephen Furlong as Chief Financial Officer MALVERN, PA
Neuronetics Appoints Stephen Furlong as Chief Financial Officer MALVERN, PA July 2, 2019 Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suff
Read more →STIMNeuronetics to Present at the JMP Life Sciences Conference
MALVERN, Pa., June 05, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics to Present at the William Blair 39th Annual Growth Stock Conference
MALVERN, Pa., May 23, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announc
Read more →STIMNeuronetics Reports First Quarter 2019 Financial and Operating Results MALVERN, Pa.
Neuronetics Reports First Quarter 2019 Financial and Operating Results MALVERN, Pa., May 07, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patie
Read more →STIMNeuronetics to Report First Quarter 2019 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 23, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today anno
Read more →STIMNeuroStar Advanced Therapy to Receive Reimbursement Approval in Japan Proven, breakthrough non-drug treatment for depression provides safe and effective option to the country s critical public health issue MALVERN, Pa
NeuroStar Advanced Therapy to Receive Reimbursement Approval in Japan Proven, breakthrough non-drug treatment for depression provides safe and effective option to the country s critical public health issue MALVERN, Pa, March 27, 2019 Neuronetics, Inc. (NASDAQ: STIM), a comme
Read more →STIMNeuronetics to Present at the 18th Annual Needham & Company Healthcare Conference
MALVERN, Pa., March 26, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics Reports Fourth Quarter and Full Year 2018 Financial and Operating Results MALVERN, PA
Neuronetics Reports Fourth Quarter and Full Year 2018 Financial and Operating Results MALVERN, PA March 5, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of
Read more →STIMNeuronetics to Report Fourth Quarter and Fiscal Year 2018 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics, Inc. Announces Appointment of Dr. Cheryl R. Blanchard to its Board of Directors Dr. Blanchard brings more than 30 years of medical device and biotechnology experience to Neuronetics MALVERN, PA
Neuronetics, Inc. Announces Appointment of Dr. Cheryl R. Blanchard to its Board of Directors Dr. Blanchard brings more than 30 years of medical device and biotechnology experience to Neuronetics MALVERN, PA, February 15, 2019 Neuronetics, Inc. (NASDAQ: STIM), a commercial stage
Read more →STIMNeuronetics Announces Preliminary Fourth Quarter and Full Year Revenue Preliminary full year 2018 total revenue of approximately $52.8 million, an increase of approximately 31% over the full year 2017, exceeding previous
Neuronetics Announces Preliminary Fourth Quarter and Full Year Revenue Preliminary full year 2018 total revenue of approximately $52.8 million, an increase of approximately 31% over the full year 2017, exceeding previously issued guidance MALVERN, PA January 7, 2019 (GLOBE NEWS
Read more →STIMNeuronetics to Present at the 30th Annual Piper Jaffray Healthcare Conference
MALVERN, Pa., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announ
Read more →STIMNeuronetics Reports Third Quarter 2018 Financial and Operating Results MALVERN, PA
Neuronetics Reports Third Quarter 2018 Financial and Operating Results MALVERN, PA November 6, 2018 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for pat
Read more →STIMNeuronetics to Report Third Quarter 2018 Financial Results and Host Conference Call
MALVERN, Pa., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today annou
Read more →STIMNeuronetics to be Added to the Russell 2000 , 3000 and Microcap Indexes
MALVERN, Pa., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who suffer from psychiatric disorders, announced t
Read more →STIMNeuronetics Reports Second Quarter 2018 Financial and Operating Results MALVERN, PA
Neuronetics Reports Second Quarter 2018 Financial and Operating Results MALVERN, PA -- August 14, 2018 Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for pat
Read more →STIMNeuronetics, Inc. to Report Second Quarter 2018 Financial Results and Host Conference Call
MALVERN, Pa., July 31, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who suffer from psychiatric disorders and the make
Read more →STIMNeuronetics, Inc., Maker of NeuroStar Advanced Therapy, Announces Closing of Initial Public Offering and the Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
MALVERN, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who suffer from psychiatric disorders and the maker of the Neuro
Read more →STIMNeuronetics, Inc., Maker of NeuroStar Advanced Therapy, Announces Pricing of Initial Public Offering
MALVERN, Pa., June 28, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who suffer from psychiatric disorders and the maker of the Neuro
Read more →STIMNeuronetics, Inc. Raises $30 Million in Series E Financing
MALVERN, PA--(Marketwire - May 16, 2011) - Neuronetics, Inc., maker of the NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy® System for the treatment of major depression*, announced today that it has completed its Series E financing totaling $30 million. Two new investor
Read more →STIMNeuronetics Receives TiE50 Award for Technology Entrepreneurship
MALVERN, PA--(Marketwire - May 9, 2011) - Neuronetics, Inc., maker of the NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy® System, has been selected by TiE Silicon Valley as a 2011 recipient of the TiE 50 Award. Neuronetics' NeuroStar TMS Therapy System is the first and
Read more →STIMNeuronetics Appoints Vice President of Health Policy and Government Relations
MALVERN, PA--(Marketwire - March 2, 2011) - Neuronetics, Inc. today announced that Mary Hailey, an industry executive with more than 25 years of experience in designing and implementing healthcare reimbursement strategies, has been appointed as Vice President, Health Policy and G
Read more →Competitive Position
How STIM ranks across every disease it competes inCompetitive Position is a premium feature
See how STIM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial